Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents
Irene G. Salado(Instituto de Química Médica), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Larissa Geiger(Centro de Investigaciones Biológicas Margarita Salas), Josefa Zaldívar-Díez(Centro de Investigaciones Biológicas Margarita Salas), Silvia González‐Pelayo(Centro de Investigaciones Biológicas Margarita Salas), Víctor Sebastián-Pérez(Centro de Investigaciones Biológicas Margarita Salas), Carmen Gil(Instituto de Salud Carlos III), Aixa V. Morales(Instituto Cajal), Daniel I. Pérez(Cedars-Sinai Medical Center), Lingling Li(Guizhou Academy of Agricultural Sciences), Nuria E. Campillo(Centro de Investigaciones Biológicas Margarita Salas)
Cited by 36
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293